Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
- Study ID
- NCT05514015
- Phase
- PHASE4
- Status
- Recruiting
Conditions
- Primary Membranous Nephropathy
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- rituximab combined with corticosteroids — DRUGInduction therapy: Rituximab intravenous infusion of 1g, d1, d15, combined with glucocorticoid therapy, oral prednisolone, initial dose of 0.5mg/(kg·d), once a day, after 8 weeks of treatment, reduce by 5mg every 4 weeks until 0.25mg/kg, this dose was maintained for 8 weeks, and then reduced by 2.5mg every 4 weeks, until 5-10mg is maintained, and the total course of treatment was about one year or so;
- rituximab — DRUGControl group (treated with Rituximab monotherapy treatment) :Rituximab intravenous infusion of 1g, d1, d15
Study Details
This was a prospective, randomized, multicenter clinical trial. Seventy-eight patients with primary membranous nephropathy (PMN) were randomly divided into intervention or control group. Intervention group was given rituximab combined with corticosteroids in induction therapy and the control group was given rituximab monotherapy. After 6 months, patients who had decreased 24h urinary protein by \> 25% but did not achieve CR were given rituximab maintenance therapy. The complete response rate at 12 months was measured.
Key Dates
- Start date
- Mar 29, 2024
- Status verified
- Apr 2024
- Primary completion
- Sep 30, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 78 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Intervention armrituximab combined with corticosteroids treatment group
- Active Comparator: Control armRituximab monotherapy treatment
Primary Outcome Measure
The complete response rate at 12 months; [ Time Frame: 12 months ]
Central Contacts
- Wei Chen8602087769673
- Qiong Wen8602087769673
Related Studies
- Study of WAL0921 in Patients With Glomerular Kidney DiseasesPHASE2 · Recruiting · Walden Biosciences · Los Angeles, California
- A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)PHASE1/PHASE2 · Recruiting · Nkarta, Inc. · Little Rock, Arkansas
- A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)PHASE3 · Recruiting · Biogen · Huntsville, Alabama
- A Phase 2 Study of Budoprutug in Subjects With Primary Membranous NephropathyPHASE2 · Recruiting · Climb Bio, Inc. · Denver, Colorado